No. The likely reason for why they have seen no DLTs is the SAR-bis-PSMA construct is much better targeted and leaks the CU67 payload less, not anything inherently to do with the use of CU67.
Unfortunately as you know from another company, once you change anything about the drug you are considered to have a new drug and have to go through the drug development process again.
Research/Valuation, page-208
- There are more pages in this discussion • 168 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.90 |
Change
-0.060(1.52%) |
Mkt cap ! $1.212B | |||
| Open | High | Low | Value | Volume |
| $3.97 | $4.12 | $3.81 | $6.449M | 1.625M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3691 | $3.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.95 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$3.90 |
Change
-0.060 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| $4.00 | $4.13 | $3.81 | 99015 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| CU6 (ASX) Chart |